Objective: We conducted two workshops to encourage “Jinsei Kaigi” to discuss advance care planning (ACP) with family members or significant others during healthy times and evaluated whether the workshops were effectively motivated participants to engage in ACP. Methods: Two workshops were held with 171 welfare commissioners, and four surveys were conducted (T1-T4) before and after the workshops. The primary endpoint was the rate of “Jinsei Kaigi” implementation, and the secondary endpoints were the Japanese versions of the ACP Engagement Survey (ACPES-J), which measures readiness for ACP, and Death Attitude Inventory (DAI), which were compared before and after the intervention, with T1 VS. T4 as the primary analysis. Results: A total of 149 participants were analyzed, and the implementation rate was 38.3%, which was a significant increase from 6% before implementation (p<.001, w=.54). Self-efficacy, readiness, and ACPES-J total scores increased significantly (p<.001 to .031, d=.29 to .67, respectively), but there were no significant changes in DAI. Conclusion: Our results suggest that workshops provide opportunities to motivate engagement in “Jinsei Kaigi”.

Objective: The Japanese version of Edmonton Functional Assessment Tool 2 (EFAT2-J) is a physical function assessment specifically for patients with advanced cancer. The purpose of this study was to examine the responsiveness of the EFAT2-J total score and to determine the clinical usefulness of the EFAT2-J. Methods: Participants were cancer patients who were being treated by a palliative care team and were not receiving curative treatment. Responsiveness was determined by comparing and correlating changes in the EFAT2-J and existing assessment scales up to approximately 2 weeks after the start of rehabilitation and calculating the standardized response means (SRM). Results: The participants were 31 patients with advanced cancer. The SRM of the EFAT2-J was large, and those of the existing assessment scales were moderate and small. Discussion: The EFAT2-J is an excellent physical function assessment that accurately captures changes in physical function in patients with advanced cancer.

This study elucidated the experiences of nurses facing challenges in assisting patients with breast cancer who are conflicted about revealing their diagnosis to their children. Seven nurses were interviewed to achieve the objectives of this study. The analysis focused on the nurses’ narratives regarding their struggles in providing support to patients with breast cancer. Following analysis, four categories were extracted from the data: “Insufficient time to support patients,” “Insufficient interprofessional coordination makes continuous involvement difficult,” “Unable to bring up the topic of explaining the illness to the child due to concern about the patient’s emotional burden,” and “Unable to intervene despite concerns that the child may realize the illness at the end, which could strain the parent-child relationship if the illness is not disclosed.” The nurses had anticipated and were concerned about the problems that would arise if the patient did not tell their child about their diagnosis and illness. However, the nurses did not have the courage to raise this topic with the patients. The findings suggest that to handle such situations, nurses should empathize with patients, understand the patients’ worries and desires, and collaborate to share patient information between medical professionals.

Objective: The effectiveness of palliative care for patients with amyotrophic lateral sclerosis (ALS) has not been fully validated. This study aimed to evaluate the impact of palliative care interventions on ALS patients using the Integrated Palliative care Outcome Scale (IPOS). Methods: A retrospective study was conducted on ALS patients at National Hospital Organization Yamagata National Hospital who received interventions from the palliative care team between November 2020 and December 2022 and were proxy-evaluated using IPOS. Results: Eleven patients were included in the analysis. Before and after the palliative care team intervention, the total IPOS score improved significantly from 24 to 18.9 (p=0.032), and the score for “Have you felt at peace” improved from 2 to 1 (p=0.031). Conclusion: Palliative care interventions may help alleviate suffering in ALS patients. However, further studies with larger sample sizes and long-term observational research are required to confirm these findings.

Introduction: Autonomic and psychiatric symptoms occur in opioid withdrawal syndrome. We report a case in which a patient treated with hydromorphone for cancer pain showed psychiatric symptoms similar to withdrawal syndrome and improved with divided administration of an extended-release tablet formulation. Case: A 60-year-old woman who underwent surgery for left breast cancer. She had been treated with hydromorphone, non-opioid analgesics, analgesic adjuvants, and nerve blocks for pain due to recurrence of lumbar metastases. However, before regular oral administration of hydromorphone extended-release, symptoms of anxiety, irritability and restlessness began to appear. Since these symptoms improved a few hours after the regular administration, we suspected the effects of opioids on blood concentration and changed the dosage to twice-daily divided doses of the same drug. As a result, symptoms decreased dramatically. Conclusion: When patients experience withdrawal-like psychiatric symptoms while taking opioids, it may be possible to alleviate these symptoms by considering the effects of decreased blood levels and adjusting the dosage of the drug, such as divided dosing.

Objective: Almost half of all patients with cancer experience dyspnea, which can have various causes. Although systemic corticosteroids are administered to relieve symptoms, their efficacy has not been established. This systematic review aims to determine the efficacy of systemic corticosteroids for dyspnea in patients with cancer. Methods: CENTRAL, MEDLINE, EMBASE, and Ichushi-Web databases were searched for articles published from their inception to September 23, 2019, on studies of systemic corticosteroid administration for dyspnea in patients with cancer. The primary outcome measure was dyspnea intensity, as assessed by patient-reported outcomes. Secondary outcome measures were quality of life, delirium, and severe adverse events. Results: Two RCTs were included in the meta-analysis. With regard to alleviating dyspnea, the systematic corticosteroid group was associated with significantly greater dyspnea relief than the placebo group (mean difference: −0.71 [95% CI: −1.4 to −0.03]). However, a meta-analysis of quality of life and delirium could not be performed due to insufficient data. Analysis of severe adverse events showed no significant difference in their incidence between the corticosteroid and control groups (relative rate: 0.96 [95% CI: 0.19-4.93]). Conclusions: Systemic corticosteroids may be effective in treating dyspnea in patients with cancer, particularly those with lung involvement. Limiting the conditions for which corticosteroids are approved is expected to promote their appropriate use and minimize their adverse effects. However, further investigation is needed to determine the appropriate dosage, and the conditions in which corticosteroids are effective.